医药生物行业周报：“AI+医疗医药”主题持续发酵，短期热度或有望延续

国都证券2025-03-05

（以下内容从国都证券《医药生物行业周报：“AI+医疗医药”主题持续发酵，短期热度或有望延续》研报附件原文摘录）核心观点一、周报摘要上周医药生物（SW）板块上涨2.71%，跑赢沪深300指数，细分板块全部上涨，医疗服务领涨。上周“AI+医疗/医药”主题概念持续发酵。海外方面，美股医疗AI代表公司之一TempusAI单周涨幅约30%，年内涨幅超160%，持续推动医疗AI概念发酵。国内方面，上周金域医学...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2517147669?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-03-05 20:09","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2517147669","market":"sh","top_or_hot":-1,"title":"医药生物行业周报：“AI+医疗医药”主题持续发酵，短期热度或有望延续","media":"国都证券","content":"<div>\n<p>（以下内容从国都证券《医药生物行业周报：“AI+医疗医药”主题持续发酵，短期热度或有望延续》研报附件原文摘录）核心观点一、周报摘要上周医药生物（SW）板块上涨2.71%，跑赢沪深300指数，细分板块全部上涨，医疗服务领涨。上周“AI+医疗/医药”主题概念持续发酵。海外方面，美股医疗AI代表公司之一TempusAI单周涨幅约30%，年内涨幅超160%，持续推动医疗AI概念发酵。国内方面，上周金域医学...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305200932963ab339&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>医药生物行业周报：“AI+医疗医药”主题持续发酵，短期热度或有望延续</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n医药生物行业周报：“AI+医疗医药”主题持续发酵，短期热度或有望延续\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-05 20:09 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305200932963ab339&s=b><strong>国都证券</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>（以下内容从国都证券《医药生物行业周报：“AI+医疗医药”主题持续发酵，短期热度或有望延续》研报附件原文摘录）核心观点一、周报摘要上周医药生物（SW）板块上涨2.71%，跑赢沪深300指数，细分板块全部上涨，医疗服务领涨。上周“AI+医疗/医药”主题概念持续发酵。海外方面，美股医疗AI代表公司之一TempusAI单周涨幅约30%，年内涨幅超160%，持续推动医疗AI概念发酵。国内方面，上周金域医学...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305200932963ab339&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"603259","symbol_name":"药明康德","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305200932963ab339&s=b","article_id":"2517147669","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305200932963ab339&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2517147669","pubTimestamp":1741176568,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"核心观点一、周报摘要上周医药生物板块上涨2.71%，跑赢沪深300指数，细分板块全部上涨，医疗服务领涨。得益于DeepSeek等国产AI大模型快速发展带来的性能提升和成本下降，“AI+医药/医疗”应用有望加速落地。海外方面，美股医疗AI代表公司之一TempusAI单周涨幅约30%，年内涨幅超160%，持续推动医疗AI概念发酵。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159891":"医疗","159938":"医药","163118":"医药生物","600568":"ST中珠","600721":"百花医药","600763":"通策医疗","603127":"昭衍新药","603259":"药明康德","603456":"九洲药业","603882":"金域医学","688046":"药康生物","688073":"毕得医药","688131":"皓元医药","688202":"美迪西","688222":"成都先导","688238":"和元生物","688246":"嘉和美康","688265":"南模生物","688315":"诺禾致源","688358":"祥生医疗","688393":"安必平","688621":"阳光诺和","688710":"益诺思","BK0239":"医药制造","BK0188":"融资融券","BK0077":"质押式回购","BK0139":"涉矿","BK0284":"社会工作","BK0132":"高送转概念","BK0060":"抗癌","000808.SH":"医药生物"},"translate_title":"Pharmaceutical and biological industry weekly report: The theme of \"AI + medical medicine\" continues to ferment, and the short-term popularity may be expected to continue","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159891":1,"159938":1,"163118":1,"600568":0.9,"600721":0.9,"600763":0.9,"603127":0.9,"603259":0.9,"603456":0.9,"603882":0.9,"688046":0.9,"688073":0.9,"688131":0.9,"688202":0.9,"688222":0.9,"688238":0.9,"688246":0.9,"688265":0.9,"688315":0.9,"688358":0.9,"688393":0.9,"688621":0.9,"688710":0.9,"000808.SH":1},"content_text":"（以下内容从国都证券《医药生物行业周报：“AI+医疗医药”主题持续发酵，短期热度或有望延续》研报附件原文摘录）核心观点一、周报摘要上周医药生物（SW）板块上涨2.71%，跑赢沪深300指数，细分板块全部上涨，医疗服务领涨。上周“AI+医疗/医药”主题概念持续发酵。海外方面，美股医疗AI代表公司之一TempusAI单周涨幅约30%，年内涨幅超160%，持续推动医疗AI概念发酵。国内方面，上周金域医学、迪安诊断、泓博医药等多家医疗/医药公司纷纷宣布接入DeepSeek并展开合作。得益于DeepSeek等国产AI大模型快速发展带来的性能提升和成本下降，“AI+医药/医疗”应用有望加速落地。我们认为“AI+医疗/医药”主题短期热度有望持续，并逐步由“主题概念”阶段过渡到“商业化落地”阶段。投资层面，持续推荐“AI+医学影像”“AI+诊断服务”“AI+药物研发”等细分领域投资机会，重点公司包括：联影医疗、迈瑞医疗、华大智造、诺禾致源、华大基因、金域医学、迪安诊断、润达医疗、美年健康、泓博医药、药明康德、成都先导、药石科技等。二、行业观点更新“AI+医疗/医药”主题持续发酵，短期热度或有望延续。上周“AI+医疗/医药”主题概念持续发酵。海外方面，美股医疗AI代表公司之一TempusAI单周涨幅约30%，年内涨幅超160%，持续推动医疗AI概念发酵。TempusAI专注于通过人工智能和机器学习技术推动精准医疗的发展，其技术平台结合了生成式人工智能、机器学习和基因组学，获得了FDA突破性认定。公司收集和分析临床、基因组和影像数据，构建大规模医疗数据库，并通过测序服务，为癌症等疾病提供精准的治疗决策支持。国内方面，上周金域医学、迪安诊断、泓博医药等多家医疗/医药公司纷纷宣布接入DeepSeek并展开合作。得益于DeepSeek等国产AI大模型快速发展带来的性能提升和成本下降，“AI+医药/医疗”应用有望加速落地。我们认为“AI+医疗/医药”主题短期热度有望延续，并逐步由“主题概念”阶段过渡到“商业化落地”阶段。投资层面，持续推荐“AI+医学影像”“AI+诊断服务”“AI+药物研发”等细分领域投资机会，重点公司包括：联影医疗、迈瑞医疗、华大智造、诺禾致源、华大基因、金域医学、迪安诊断、润达医疗、美年健康、泓博医药、药明康德、成都先导、药石科技等。三、行业表现跟踪上周（2.10-2.14）医药生物（SW）板块上涨2.71%，在2021版31个申万一级行业中，表现排名第5位，同期沪深300指数上涨1.19%。细分子板块来看，上涨所有细分板块均上涨，涨幅由大到小分别为医疗服务（+6.51%）、医疗器械（+4.81%）、医药商业（+4.18%）、生物制品（+1.61%）、中药（+0.80%）和化学制药（+0.71%）。个股表现来看，涨幅排名前五的个股分别是迪安诊断（+46.29%）、美年健康（+31.58%）、安必平（+28.19%）、华大智造（+27.33%）和复旦复华（+25.04%）；跌幅排名前五的个股分别是贝达药业（-11.36%）、*ST吉药（-8.85%）、*ST普利（-6.34%）、广生堂（-5.99%）和人福医药（-5.35%）。估值方面来看，截至2月14日，医药生物（SW）市盈率（TTM，剔除负值）为26.68x，持续低于2010年以来中位数水平，相较全部A股的估值溢价率为74.95%，同样持续低于2010年以来的中位数水平。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2517147669","isCrawlerRequest":true}